Medtronic’s MiniMed 780G System cleared by FDA for Type 1 and 2 diabetes

Medtronic (MDT) announced two FDA regulatory milestones that broaden the MiniMed 780G system portfolio: clearance of the SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with the Instinct sensor, made by Abbott (ABT), for type 1 diabetes, and approval of the MiniMed 780G system for use in adults 18+ with insulin-requiring type 2 diabetes. This clearance, alongside the previously cleared MiniMed 780G insulin pump as an alternate controller enabled pump, completes the Medtronic FDA pre-market approval pathway for the Instinct sensor integration with its MiniMed 780G system for people living with type 1 diabetes. The Instinct sensor, designed exclusively by Abbott for MiniMed automated insulin delivery and Smart MDI systems, is an integrated CGM offering a wear time of up to 15 days. In the coming weeks, Medtronic and Abbott plan to complete their required compliance documentation enabling sensor integration and marketing. Completion of this step will finalize the regulatory process, after which ordering for the Instinct sensor with the MiniMed 780G system will begin. Pre-orders for Simplera Sync sensor will also begin later this month.